Sitemap

Site Configurations
Company
  1. Who We Are
    1. Global Organization
    2. History
    3. Our Leadership Team
      1. Chris Round
      2. Miguel Fernández Alcalde
      3. BoonHuey Ee
      4. Eduardo Fabiano
      5. Betania Glorio
      6. Libby Horne
      7. Lori Lebson
      8. Michael MacDougall
      9. Gaby Murphy
      10. Terri Stewart
      11. Venkat Thiruvallur
      12. Sarah Turner
      13. Joel VanderMeulen
      14. Dan Van Horn
      15. Emily Vlasak
      16. Lisa Walsh
  3. Vibrant Thoughts
    1. Cycling Inspiration Through the Community
    2. Remembering the Hopes and Dreams of Future Fathers
    3. Clinical Trials Won’t Ever Be the Same & Why That’s a Good Thing
    4. COVID’s Costs on Workplace Equality – How Women Have Overpaid
    5. A Gathering of the Minds to Help Generations to Come
    6. Kick Starting 2022
    7. “I’M IN” to Deliver on Diversity for Patients
    8. Small Steps Make a Big Impact: Moving from Conservation to Sustainability
    9. 31 Days to Recognize Bladder Cancer Awareness Month
    10. Top 5 Family-Building Tips for LGBTQ+ Communities
    11. Finding the Value in VBCs
    12. 25+ Years of Commitment… and Still Going Strong for the HIV Community
    13. WE WILL Deliver on Our Future
    14. Community Matters in Multiple Sclerosis
    15. “Moving” to Support Those with Head and Neck Cancer
    16. Our Military and Veterans Deserve to Build Their Families
    17. Making Patient-Directed the “New Normal”
    18. Reflecting on a Childhood Love for Science this "Back to School" Season
  5. Contact Us
  6. Partnering
  7. Corporate Responsibility
    1. Embracing Carers
    2. Healthy Women, Healthy Economies
    3. Environmental Commitment
    4. Corporate Giving
    5. Patient Safety
  9. News
    1. Press Releases
      1. 2023-05-25 ASCO 2023 Highlights
      2. 2023-03-27 Merck KGaA, Darmstadt, Germany Regains Exclusive Worldwide Rights to BAVENCIO®
      3. 2023-02-23 ACTRIMS 2023
      4. 2023-02-13 New Analyses Reinforce Survival Benefit of BAVENCIO
      5. 2022-12-22 Mersana ADC Collaboration
      6. 2022-11-21 Research and Development Update
      7. 2022-10-26 New Data for Evobrutinib
      8. 2022-10-26 EMD Serono Showcases Depth of MS Portfolio at ECTRIMS
      9. 2022-09-21 Nerviano Collaboration
      10. 2022-09-07 ESMO 2022 xevinapant Five Year Data
      11. 2022-09-07 EMD Serono to Highlight Data at ESMO 2022
      12. 2022-06-04 EMD Serono advances development programs in oncology
      13. 2022-05-26 ASCO 2022 Highlights
      14. 2022-03-31 Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022
      15. 2022-02-24 New MAVENCLAD® Data at ACTRIMS Forum 2022
      16. 2022-02-18 TEPMETKO® for Patients with Advanced NSCLC with METex14 Skipping Alterations
      17. 2022-02-18 BAVENCIO® First-Line Maintenance Treatment of Advanced UC Patients
      18. 2022-02-17 Sustainable Slim Pack for Fertility Medication
      19. 2021-12-17 TEPMETKO receives positive CHMP opinion
      20. 2021-11-29 EMD Serono Launches New Fertility LifeLines™ Portal
      21. 2021-11-17 New Data Show Dramatic Emotional Toll of Pandemic on Unpaid Caregivers of Peopl
      22. 2021-10-14 New Data Presented at ECTRIMS Show Evobrutinib
      23. 2021-10-13 New Real-World MAVENCLAD® Data
      24. 2021-10-04 EMD Serono Completes Enrollment of Evobrutinib ECTRIMS 2021
      25. 2021-09-13 ESMO WCLC 2021 Highlights
      26. 2021-05-19 ASCO21 Data
      27. 2021-04-23 New Data for MAVENCLAD® Use During the COVID-19 Pandemic
      28. 2021-04-16 Evobrutinib is the First and Only BTK Inhibitor
      29. 2021-04-12 EMD Serono Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer
      30. 2021-03-16 Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
      31. 2021-03-01 Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
      32. 2021-02-25 New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients
      33. 2021-02-09 Real-World Evidence Study at Miami CFAR Suggests HIV-Associated Wasting Remains an Underappreciated Comorbidity
      34. 2021-02-04 Merck KGaA, Darmstadt, Germany, Announces Leadership Change for North America and Global Innovative Medicine Franchises in Healthcare
      35. 2021-02-03 FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations
      36. 2021-01-25 European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment
      37. 2021-01-20 Merck KGaA, Darmstadt, Germany Announces Update on the INTR@PID Clinical Program Including Lung 037 Study
      38. 2020-12-11 BAVENCIO® (avelumab) Receives Positive CHMP Opinion
      39. 2020-11-18 EMD Serono's Embracing Carers™ Announces Study Results on COVID-19 and Caregive
      40. 2020-10-15 EMD Serono Announces Retirement of Dr. Luciano Rossetti
      41. 2020-09-18 BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published
      42. 2020-09-13 ESMO 2020 - Oncology Portfolio and Pipeline with Data in Multiple Cancers
      43. 2020-09-11 Merck KGaA - Positive Phase II Results for Investigational Sonelokinab (M1095)
      44. 2020-09-03 EMD Serono - New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting
      45. 2020-08-25 FDA Accepts Filing of New Drug Application for Tepotinib
      46. 2020-08-05 EMD Serono statement on Rebif® (interferon beta-1a) for the ACTT 3 trial
      47. 2020-06-30 FDA Approves BAVENCIO as First-Line Maintenance Treatment
      48. 2020-06-25 First Clinical Trial of TLR7 and 8 Inhibitor as a Potential Treatment for Sever
      49. 2020-06-08 EMD Serono Announces Launch of MS in the 21st Century Website
      50. 2020-05-29 New England Journal of Medicine: Primary Analysis of VISION Data for Tepotinib
      51. 2020-05-28 Merck KGaAand Twitch Join Forces on World Multiple Sclerosis Day
      52. 2020-05-27 Rebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information
      53. 2020-05-23 Evobrutinib First BTK Inhibitor to Report Efficacy+Safety in MS Over 108 Weeks
      54. 2020-05-13 Breakthrough Innovation in Cancer Care to Be Presented at ASCO 2020
      55. 2022-04-30 EMD Serono - ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care
      56. 2020-04-09 EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO®
      57. 2020-03-25 TEPMETKO® (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations
      58. 2020-03-19 Combating the Spread of COVID-19
      59. 2020-03-18 2020-03-18 Merck KGaA statement updates for the INTR@PID Lung 037 study
      60. 2020-03-13 EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
      61. 2020-01-09 EMD Serono and MyHealthTeams Launch Family Planning Resource Center to Provide Families Affected by Multiple Sclerosis
      62. 2020-01-06 BAVENCIO Improved Overall Survival in Patients With Urothelial Carcinoma
    3. Download Gallery
      1. Sites & Buildings
        1. EMD Serono Headquarters, Rockland, MA - Exterior
        2. EMD Serono R&D Institute, Billerica, MA - Company Logo on Building
        3. EMD Serono R&D Institute, Billerica, MA - Aerial View
        4. EMD Serono R&D Institute, Billerica, MA - Cafeteria Booths
        5. EMD Serono R&D Institute, Billerica, MA - Cafeteria
        6. EMD Serono R&D Institute, Billerica, MA - Laboratory
        7. EMD Serono R&D Institute, Billerica, MA - Sculpture
      3. Logos
        1. EMD Serono Logo Red
        2. EMD Serono Logo Cyan
        3. EMD Serono Logo Yellow
      5. b-roll
        1. EMD Serono R&D Institute, Billerica, MA - B-Roll
        2. EMD Serono Headquarters, Rockland, MA - B-Roll
    5. Press Release Archive
Expertise
Research
Careers
Patients and Caregivers
Compliance & Transparency
Sitemap
wip